# Vitamina E (Alfa-Tocoferol) - Quick Clinical Reference

**Score Item ID:** 80ffc2b2-545b-4389-891f-b6aba1f7865c

---

## Reference Ranges

| Parameter | Normal | Deficiency |
|-----------|--------|------------|
| Serum Alpha-Tocopherol | 5-18 mg/L | <5 mg/L |
| Alpha-Tocopherol/Lipids Ratio | >0.8 mg/g | <0.8 mg/g |

**Note:** Ratio is more accurate in hyperlipidemia

---

## When to Order

- Suspected malabsorption (chronic diarrhea, steatorrhea)
- Unexplained neuropathy/ataxia
- Cystic fibrosis, celiac disease, Crohn's disease
- Chronic cholestatic liver disease
- Suspected abetalipoproteinemia
- NAFLD/NASH management

---

## Deficiency Symptoms (Red Flags)

**Neurological:**
- Progressive peripheral neuropathy
- Spinocerebellar ataxia
- Hyporeflexia → areflexia
- Ophthalmoplegia (upward gaze limitation)
- Proprioception loss

**Muscular:**
- Profound muscle weakness
- Difficulty walking/coordination

**Visual:**
- Retinopathy
- Visual field constriction
- Blindness (severe cases)

**Other:**
- Hemolytic anemia
- Cardiac arrhythmias (severe)

---

## Supplementation Dosing

### Deficiency Treatment

| Severity | Dose | Duration |
|----------|------|----------|
| **Mild** | 15-25 mg/day (22.5-37.5 IU/day) | Until normalization |
| **Moderate** | 100-800 IU/day | 3-6 months minimum |
| **Severe/Neurological** | 100-800 IU/day | Long-term |
| **Abetalipoproteinemia** | 100-200 IU/kg/day | Lifelong |

**Administration:** With fat-containing meals

### NASH Treatment (Evidence-Based)

- **Indication:** Non-diabetic adults, no cirrhosis, biopsy-confirmed aggressive NASH
- **Dose:** 800 IU/day
- **Duration:** 18-24 months minimum
- **Monitoring:** Transaminases every 3 months
- **Expected:** ↓ ALT/AST, ↓ steatosis, ↓ inflammation
- **Not expected:** Fibrosis improvement

---

## Safety Alerts

### ⚠️ High-Dose Risks (>1000 mg/day)

- Hemorrhagic stroke
- Pro-oxidant effects
- Liver toxicity

### ⚠️ Drug Interactions

- **Anticoagulants:** Increased bleeding risk
- **Statins:** May reduce efficacy
- **Fat-chelating drugs:** Reduced vitamin E absorption

### ⚠️ Not Indicated For

- Primary prevention of cardiovascular disease (USPSTF 2022)
- Primary prevention of cancer (USPSTF 2022)
- General "antioxidant" supplementation

---

## Monitoring Protocol

### Initial Assessment
1. Serum alpha-tocopherol (8-12h fasting)
2. Complete lipid profile
3. Calculate alpha-tocopherol/lipids ratio
4. Liver function tests
5. Neurological examination

### Follow-Up
- **3 months:** Repeat alpha-tocopherol, adjust dose
- **6 months:** Comprehensive reassessment
- **Neurological cases:** Clinical exam every 3 months, MRI at 6-12 months
- **NASH:** Transaminases every 3 months

### Long-Term
- Reassess every 6-12 months even after normalization
- Monitor for medication changes affecting absorption
- Screen for new malabsorption symptoms

---

## Workup for Low Levels

1. **Confirm deficiency:** Repeat test + lipid ratio
2. **History:**
   - Chronic diarrhea, steatorrhea
   - Fat malabsorption symptoms
   - Family history (abetalipoproteinemia)
   - Medications (orlistat, cholestyramine)

3. **Lab investigation:**
   - Fecal elastase
   - Fecal fat (72h collection)
   - Celiac panel (tTG-IgA, total IgA)
   - Calprotectin
   - Liver function tests
   - Apolipoproteins (if suspect abetalipoproteinemia)

4. **Imaging:**
   - Abdominal ultrasound (cholestasis, hepatobiliary disease)
   - MRI enterography (Crohn's disease)

5. **Specialized testing:**
   - Sweat test (cystic fibrosis)
   - Genetic testing (abetalipoproteinemia, cystic fibrosis)

---

## Recent Evidence (2021-2025)

### Key Findings

**Antioxidant-Independent Mechanisms (2025)**
- Modulates gene expression beyond antioxidant activity
- Affects cholesterol biosynthesis
- Clinical implications for cardiovascular health

**NASH Meta-Analysis (2021)**
- Significant transaminase reduction
- Histological improvement (steatosis, inflammation)
- No consistent fibrosis benefit
- Recommend for aggressive histology only

**Metabolome Variability (2021)**
- Marked interindividual variability in vitamin E levels
- Explains inconsistent clinical trial results
- Supports need for personalized dosing

**Safety Review (2025)**
- Confirms high-dose risks (>1000 mg/day)
- Pro-oxidant effects at supraphysiological doses
- Liver toxicity concerns
- Balanced risk-benefit assessment needed

---

## Quick Decision Tree

```
Low Vitamin E (<5 mg/L or ratio <0.8)
    ↓
Symptoms present?
    ↓
YES → Urgent workup + immediate supplementation
    ↓
NO → Investigate cause before supplementing
    ↓
Malabsorption identified?
    ↓
YES → Treat underlying cause + supplement
    ↓
NO → Consider genetic causes (abetalipoproteinemia)
    ↓
Supplement according to severity
    ↓
Monitor at 3 months
    ↓
Adjust dose based on response
    ↓
Long-term monitoring every 6-12 months
```

---

## Red Flags Requiring Urgent Referral

- Progressive neurological symptoms
- Rapidly worsening ataxia
- Vision loss
- Severe muscle weakness preventing ambulation
- Suspected abetalipoproteinemia (very low cholesterol + vitamin E deficiency)
- Pediatric cases (higher risk of permanent neurological damage)

---

## References (PubMed)

1. **PMID 39978678** - Antioxidant-independent activities (J Biol Chem, 2025)
2. **PMID 40065887** - Clinical role and adverse risks review (Cureus, 2025)
3. **PMID 32810309** - NAFLD meta-analysis (J Gastroenterol Hepatol, 2021)
4. **PMID 33503988** - Metabolome variability (Antioxidants, 2021)

---

**Last Updated:** 2026-01-29
**Database Status:** ✅ Fully Enriched (13 linked articles)
